News | April 24, 2014

Singulex’s Ultrasensitive Research Test for Cardiac Troponin-I Predicts Coronary Heart Disease

Cardiovascular risk assessment results highlighted at American Heart Association Epidemiology and Prevention Conference

Singulex Blood Test Clinical Study American Heart Association

April 24, 2014 — Singulex Inc. presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the company’s proprietary ultrasensitive Erenna Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.

“In this large prospective study utilizing Singulex’s uniquely sensitive technology, we were able to measure troponin-I in virtually every patient in the cohort,” said Wolfgang Koenig, M.D., Ph.D., FRCP, FESC, FACC, FAHA, professor of medicine/cardiology at the Department of Internal Medicine – II Cardiology at the University of Ulm Medical School, Ulm, Germany. “The results demonstrate that Singulex’s research troponin-I test can predict incident coronary heart disease in the general population which, I believe, ultimately brings greater insight into the cardiovascular risk profile of individuals who have not already been diagnosed with the disease.”

The study, led by Koenig, focused on the association between increased concentrations of cardiac troponin-I and increased risk of CHD. The population-based study was the first with significant long-term follow-up to demonstrate that modestly increased concentrations of cardiac troponin-I are linked to future CHD events.

The study was conducted in middle-aged healthy men and women without known heart disease at the time of study entry within the MONICA/KORA Augsburg studies. Serum levels of cardiac troponin-I were available in 2,745 men and women, and included 803 new cases of CHD. The average baseline concentration, or level, of cardiac troponin-I across all of the 2,745 subjects was 1.56 ng/L (1.56 pg/mL). Baseline concentrations of cardiac troponin-I were higher in CHD cases compared to non-cases (mean 2.56 vs. 1.49 ng/L, p<0.0001). After adjustment for variables of the Framingham Risk Score, the hazard ratio (HR) with 95% confidence interval (CI) for a CHD event in the top quartile (subjects with the highest cardiac troponin-I levels) compared to the bottom quartile (subjects with the lowest cardiac troponin-I values) was 2.76 (95% CI, 1.87-4.09). Thus, there was a 2.76 fold increase in risk for developing coronary heart disease in the patients with high baseline cardiac troponin-I levels compared to patients with low baseline levels. After additional adjustment for alcohol intake, physical activity and body mass index, relative risk remained essentially unchanged. Singulex’s SMC technology measured cTnI at the picogram/mL level and predicted which patients would develop CHD.

The poster, Ultrasensitive troponin-I, strongly predicts incident coronary heart disease in the general population independently of traditional risk factors. Results from the MONICA/KORA Augsburg Case-Cohort Study, by Wolfgang Koenig, M.D., et al, was presented at the 2014 American Heart Association Epidemiology and Prevention Scientific Sessions that are being held at the Hilton San Francisco Union Square in San Francisco.

For more information: www.singulex.com

 

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Overlay Init